Who depends on Da Vita
1 listed supplier reports Da Vita as a customer worth 10% or more of their revenue, led by Akebia Therapeutics at 25%.
Get an email when Da Vita's customer concentration changes
When a new annual report adds a 10% customer, drops one, or moves a share by 5 points or more, you get the change and the filing link. Up to 10 companies per address, no account, unsubscribe with one click.
Suppliers that depend on Da Vita
Listed companies whose annual report names Da Vita as a customer worth 10% or more of their revenue. If Da Vita cuts orders or switches supplier, these are the companies that feel it.
| Supplier | Its revenue from this company | Change vs prior year | History | Latest filing |
|---|---|---|---|---|
| Akebia TherapeuticsAKBA | 25% | new | 1 year | FY 2025 · filed 26 Feb 2026 |
About this data
US-listed companies must disclose revenue from any single customer that reaches 10% of their total (ASC 280). ShadowGraph reads these disclosures from the XBRL data of every 10-K and 20-F we scan, keeps one value per fiscal year (restatements replace earlier values) and links each number to its filing. Companies that describe a customer only as "Customer A" are not listed by name. Figures are as reported; nothing here is investment advice.
All companies · Latest dependency shifts · Bulk data and API